Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1

Vaccine

Volumn 29, Issue 15, 2011, Pages 2672-2678

  Xu, Wen ^a   Liu, Jianxiao ^a   Gong, Wenci ^a   Chen, Jun ^a   Zhu, Shanli ^a   Zhang, Lifang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chlamydia trachomatis; DNA vaccine; Human papillomavirus; Major outer membrane protein

Indexed keywords

CAPSID PROTEIN L1; DNA VACCINE; GAMMA INTERFERON; HPV6BL1/CT MOMP 168; IMMUNOGLOBULIN G2A; OUTER MEMBRANE PROTEIN; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL STRAIN COS7; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GENITAL TRACT INFECTION; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; IMMUNOPRECIPITATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CAPSID PROTEINS; EPITOPES; FEMALE; INJECTIONS, INTRAMUSCULAR; LYMPHOGRANULOMA VENEREUM; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PORINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 79952243214     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.132     Document Type: Article

References (32)

1. Andersen B., Ostergaard L., Puho E., Skriver M.V., Schonheyder H.C. Ectopic pregnancies and reproductive capacity after Chlamydia trachomatis positive and negative test results: a historical follow-up study. Sex Transm Dis 2005, 32(June (6)):377-381.
2. Arya R., Mannion P.T., Woodcock K., Haddad N.G. Incidence of genital Chlamydia trachomatis infection in the male partners attending an infertility clinic. J Obstet Gynaecol 2005, 25(May (4)):364-367.
3. 2+ dependent manner in human macrophages. Comp Immunol Microbiol Infect Dis 2009 September 24.
4. Kilmarx P.H., Mock P.A., Levine W.C. Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretions. Sex Transm Dis 2001, 28(June (6)):347-348.
5. Koskela P., Anttila T., Bjorge T., Brunsvig A., Dillner J., Hakama M., et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000, 85(January (1)):35-39.
6. Schellenbacher C., Roden R., Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009, 83(October (19)):10085-10095.
7. Berg M., Gambhira R., Siracusa M., Hoiczyk E., Roden R., Ketner G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine 2007, 25(April (17)):3501-3510.
8. Xu Y.F., Zhang Y.Q., Xu X.M., Song G.X. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol 2006, 151(November (11)):2133-2148.
9. Ortiz L., Demick K.P., Petersen J.W., Polka M., Rudersdorf R.A., Van der Pol B., et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol 1996, 157(November (10)):4554-4567.
10. 8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. J Immunol 1999, 162(June (11)):6855-6866.
11. Batteiger B.E. The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific epitope. Infect Immun 1996, 64(February (2)):542-547.
12. Zhu S.L., Shi Z.H., Li W.S., Chen J., Zhang L.F. Immunogenicity of multi-epitopes gene of major outer membrane protein of Chlamydia trachomatis. Zhonghua Yu Fang Yi Xue Za Zhi 2009, 43(March (3)):232-236.
13. Holland M.J., Conway D.J., Blanchard T.J., Mahdi O.M., Bailey R.L., Whittle H.C., et al. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin Exp Immunol 1997, 107(January (1)):44-49.
14. Starnbach M.N., Bevan M.J., Lampe M.F. Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars. Infect Immun 1995, 63(September (9)):3527-3530.
15. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182(June (12)):8063-8070.
16. Komoda T. Kinetic study of antibodies (IgG, IgA) to Chlamydia trachomatis: importance of IgA antibody in screening test for C. trachomatis infection by peptide-based enzyme immunosorbent assay. Jpn J Infect Dis 2007, 60(November (6)):347-351.
17. Eko F.O., He Q., Brown T., McMillan L., Ifere G.O., Ananaba G.A., et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 2004, 173(September (5)):3375-3382.
18. Dong-Ji Z., Yang X., Shen C., Lu H., Murdin A., Brunham R.C. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun 2000, 68(June (6)):3074-3078.
19. Zhang D., Yang X., Berry J., Shen C., McClarty G., Brunham R.C. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis 1997, 176(October (4)):1035-1040.
20. Park M.A., Kim H.J., Kim H.J. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 2008, 59(May (1)):175-181.
21. Peng S., Frazer I.H., Fernando G.J., Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998, 240(January (1)):147-157.
22. Bontkes H.J., Ruizendaal J.J., Kramer D., Meijer C.J., Hooijberg E. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 2005, 96(March (3)):897-901.
23. Lenz P., Lowy D.R., Schiller J.T. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 2005, 35(May (5)):1548-1556.
24. Lenz P., Thompson C.D., Day P.M., Bacot S.M., Lowy D.R., Schiller J.T. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003, 106(March (3)):231-237.
25. Da Silva D.M., Velders M.P., Nieland J.D., Schiller J.T., Nickoloff B.J., Kast W.M. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 2001, 13(May (5)):633-641.
26. Stephens R.S., Poteralski J.M., Olinger L. Interaction of Chlamydia trachomatis with mammalian cells is independent of host cell surface heparan sulfate glycosaminoglycans. Infect Immun 2006, 74(March (3)):1795-1799.
27. Payne E., Bowles M.R., Don A., Hancock J.F., McMillan N.A. Human papillomavirus type 6b virus-like particles are able to activate the Ras-MAP kinase pathway and induce cell proliferation. J Virol 2001, 75(May (9)):4150-4157.
28. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 1997, 71(March (3)):2449-2456.
29. Lu H., Xing Z., Brunham R.C. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol 2002, 169(December (11)):6324-6331.
30. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 2004, 72(February (2)):1019-1028.
31. Eko F.O., Barisani-Asenbauer T., Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum Vaccin 2008, 4(May-Jun (3)):176-183.
32. Igietseme J.U., Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun 2000, 68(December (12)):6798-6806.